Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8002957 | 0.84 | TAAR1 (0.41) | TAAR1CES2CES1TRPA1ADRA2A | |
| SCHEMBL4074988 | 0.83 | TAAR1 (0.50) | TAAR1CES2CES1TRPA1ADRA2A | |
| SCHEMBL13590015 | 0.82 | CES2 (0.50) | TAAR1CES2CES1TRPA1CYP2D6 | |
| SCHEMBL4456759 | 0.82 | CES2 (0.50) | TAAR1CES2CES1TRPA1CYP2D6 | |
| SCHEMBL10778622 | 0.81 | TAAR1 (0.43) | TAAR1CES2CES1TRPA1ADRA2A | |
| SCHEMBL9523477 | 0.79 | TAAR1 (0.46) | TAAR1CES2CES1TRPA1ADRA2A | |
| Bicarbonate SCHEMBL5784405 | 0.79 | PTGS2 (0.58) | TAAR1LMNAALDH1A1TDP1 | |
| SCHEMBL2238871 | 0.78 | TRPA1 (0.48) | TAAR1CES2CES1TRPA1ADRA2A | |
| Benzene SCHEMBL22288204 | 0.77 | TAAR1 (0.48) | TAAR1CES2CES1TRPA1ADRA2A | |
| SCHEMBL14127281 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649477-B1 | POLARISATION TRANSFER VIA A SECOND METAL COMPLEX | UNIV YORK (GB) | 2024-08-14 | — | — | EP | disclosed |
| CN-105189515-B | Furopyridine class as bromine structural domain inhibitor | 葛兰素史克知识产权第二有限公司 | 2018-07-03 | — | — | CN | disclosed |
| EP-2970323-B1 | FUROPYRIDINES AS BROMODOMAIN INHIBITORS. | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 2) LTD (GB) | 2017-10-18 | — | — | EP | disclosed |
| US-9670221-B2 | Furopyridines as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2017-06-06 | — | — | US | disclosed |
| US-9663533-B2 | Thieno[3,2-C]pyridin-4(5H)-ones as BET inhibitors | GLAXOSMITHKLINE LLC (US) | 2017-05-30 | — | — | US | disclosed |
| EP-2920183-B1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20160297832-A1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | GLAXOSMITHKLINE LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160016966-A1 | FUROPYRIDINES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-01-21 | — | — | US | disclosed |
| EP-2970323-A1 | FUROPYRIDINES AS BROMODOMAIN INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2016-01-20 | — | — | EP | disclosed |
| EP-2920183-A1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | Glaxosmithkline LLC (US) | 2015-09-23 | — | — | EP | disclosed |
| WO-2014140077-A1 | FUROPYRIDINES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014078257-A1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-05-22 | — | — | WO | disclosed |
| US-5264436-A | Alpha-adrenoceptors antagonist, hypotensive agents or antidiabetic agents | BEECHAM GROUP P.L.C. (GB) | 1993-11-23 | — | — | US | disclosed |
| EP-0275639-B1 | N-SUBSTITUTED CYCLIC AMIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BEECHAM GROUP PLC (GB) | 1992-07-15 | — | — | EP | disclosed |
| US-5077299-A | Glaucoma, antidepressants, anticoagulants, hypotensive agents | BEECHAM GROUP P.L.C. (GB) | 1991-12-31 | — | — | US | disclosed |
| US-4918083-A | 4,5 Dihydroimidazole compounds which have useful pharmaceutical utility | BEECHAM GROUP P.L.C. (GB) | 1990-04-17 | — | — | US | disclosed |
| EP-0275639-A1 | N-substituted cyclic amides, their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1988-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297832-A1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | BRD4, BET1, BRD3 | TAAR1 614/4885CES2 2613/4885CES1 1692/4885 |
| US-20160016966-A1 | FUROPYRIDINES AS BROMODOMAIN INHIBITORS | BRD3, BRD4, BRPF3 | TAAR1 3457/4885CES2 872/4885CES1 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.